Drug Profile
House dust mite allergy vaccine - HAL Allergy
Alternative Names: Purethal MitesLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator HAL Allergy
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 22 Mar 2022 No development reported - Phase-III for Allergic rhinitis in Slovakia, Portugal, Spain (SC) (HAL Allergy pipeline, March 2022)
- 22 Mar 2022 No development reported - Phase-III for Allergic rhinoconjunctivitis in Portugal, Slovakia, Spain (SC) (HAL Allergy pipeline, March 2022)
- 12 Aug 2016 Phase-III clinical trials in Allergic rhinoconjunctivitis and Allergic rhinitis in Hungary (SC) (EudraCT2016-000051-27)